Role of FGFR3 in urothelial cell carcinoma: Biomarker and potential therapeutic target

World Journal of Urology

Volumn 25, Issue 6, 2007, Pages 581-593

  Knowles, Margaret A ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Biomarker; Bladder cancer; Expression; FGFR3; Mutation; Therapeutic target

Indexed keywords

ANTINEOPLASTIC AGENT; FIBROBLAST GROWTH FACTOR RECEPTOR 3; TUMOR MARKER;

BLADDER TUMOR; CANCER STAGING; CELL TRANSFORMATION; DRUG EFFECT; GENETICS; HUMAN; METABOLISM; METHODOLOGY; MUTATION; NUCLEOTIDE SEQUENCE; PROGNOSIS; REVIEW; RISK FACTOR;

ANTINEOPLASTIC AGENTS; CELL TRANSFORMATION, NEOPLASTIC; DNA MUTATIONAL ANALYSIS; HUMANS; MUTATION; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 36248943079     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-007-0213-4     Document Type: Review

References (98)

1. Johnson DE, Williams LT (1993) Structural and functional diversity in the FGF receptor multigene family. Adv Cancer Res 60:1-41
2. Avivi A, Yayon A, Givol D (1993) A novel form of FGF receptor-3 using an alternative exon in the immunoglobulin domain III. FEBS Lett 330:249-252
3. Ornitz DM, Xu J, Colvin JS et al (1996) Receptor specificity of the fibroblast growth factor family. J Biol Chem 271:15292-15297
4. Werner S, Duan DS, de Vries C, Peters KG, Johnson DE, Williams LT (1992) Differential splicing in the extracellular region of fibroblast growth factor receptor 1 generates receptor variants with different ligand-binding specificities. Mol Cell Biol 12:82-88
5. Chellaiah AT, McEwen DG, Werner S, Xu J, Ornitz DM (1994) Fibroblast growth factor receptor (FGFR) 3. Alternative splicing in immunoglobulin-like domain III creates a receptor highly specific for acidic FGF/FGF-1. J Biol Chem 269:11620-11627
6. Passos-Bueno MR, Wilcox WR, Jabs EW, Sertie AL, Alonso LG, Kitoh H (1999) Clinical spectrum of fibroblast growth factor receptor mutations. Hum Mutat 14:115-125
7. Chen L, Li C, Qiao W, Xu X, Deng C (2001) A Ser(365)->Cys mutation of fibroblast growth factor receptor 3 in mouse downregulates Ihh/PTHrP signals and causes severe achondroplasia. Hum Mol Genet 10:457-465
8. Colvin JS, Bohne BA, Harding GW, McEwen DG, Ornitz DM (1996) Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3. Nat Genet 12:390-397
9. Cappellen D, De Oliveira C, Ricol D et al (1999) Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet 23:18-20
10. Bakkar AA, Wallerand H, Radvanyi F et al (2003) FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder. Cancer Res 63:8108-8112
11. Billerey C, Chopin D, Aubriot-Lorton MH et al (2001) Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am J Pathol 158:1955-1959
12. Hernandez S, Lopez-Knowles E, Lloreta J et al (2005) FGFR3 and Tp53 mutations in T1G3 transitional bladder carcinomas: Independent distribution and lack of association with prognosis. Clin Cancer Res 11:5444
13. Kimura T, Suzuki H, Ohashi T, Asano K, Kiyota H, Eto Y (2001) The incidence of thanatophoric dysplasia mutations in FGFR3 gene is higher in low-grade or superficial bladder carcinomas. Cancer 92:2555-2561
14. Rieger-Christ KM, Mourtzinos A, Lee PJ et al (2003) Identification of fibroblast growth factor receptor 3 mutations in urine sediment DNA samples complements cytology in bladder tumor detection. Cancer 98:737-744
15. Sibley K, Cuthbert-Heavens D, Knowles MA (2001) Loss of heterozygosity at 4p16.3 and mutation of FGFR3 in transitional cell carcinoma. Oncogene 20:686-691
16. van Rhijn BW, Lurkin I, Chopin DK et al (2003) Combined microsatellite and FGFR3 mutation analysis enables a highly sensitive detection of urothelial cell carcinoma in voided urine. Clin Cancer Res 9:257-263
17. van Rhijn BW, Lurkin I, Radvanyi F, Kirkels WJ, van der Kwast TH, Zwarthoff EC (2001) The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. Cancer Res 61:1265-8
18. van Rhijn BW, Montironi R, Zwarthoff EC, Jobsis AC, van der Kwast TH (2002) Frequent FGFR3 mutations in urothelial papilloma. J Pathol 198:245-251
19. van Rhijn BW, van Tilborg AA, Lurkin I et al (2002) Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disorders. Eur J Hum Genet 10:819-824
20. van Rhijn BW, Vis AN, van der Kwast TH et al (2003) Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome. J Clin Oncol 21:1912-1921
21. Wallerand H, Bakkar AA, de Medina SG et al (2005) Mutations in TP53, but not FGFR3, in urothelial cell carcinoma of the bladder are influenced by smoking: Contribution of exogenous versus endogenous carcinogens. Carcinogenesis 26:177
22. WHO (2004) WHO classification tumours of the urinary system and male genital organs. IARC Press, Lyon
23. Adar R, Monsonego-Ornan E, David P, Yayon A (2002) Differential activation of cysteine-substitution mutants of fibroblast growth factor receptor 3 is determined by cysteine localization. J Bone Miner Res 17:860-868
24. Hernandez S, Lopez-Knowles E, Lloreta J et al (2006) Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas. J Clin Oncol 24:3664-3671
25. Chesi M, Brents LA, Ely SA et al (2001) Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma. Blood 97:729-736
26. Wu R, Connolly D, Ngelangel C, Bosch FX, Munoz N, Cho KR (2000) Somatic mutations of fibroblast growth factor receptor 3 (FGFR3) are uncommon in carcinomas of the uterine cervix. Oncogene 19:5543-5546
27. Karoui M, Hofmann-Radvanyi H, Zimmermann U et al (2001) No evidence of somatic FGFR3 mutation in various types of carcinoma. Oncogene 20:5059-5061
28. Naimi B, Latil A, Berthon P, Cussenot O (2000) No evidence for fibroblast growth factor receptor 3 (FGFR-3) R248C/S249C mutations in human prostate cancer. Int J Cancer 87:455-456
29. Sibley K, Stern P, Knowles MA (2001) Frequency of fibroblast growth factor receptor 3 mutations in sporadic tumours. Oncogene 20:4416-4418
30. Jang JH, Shin KH, Park JG (2001) Mutations in fibroblast growth factor receptor 2 and fibroblast growth factor receptor 3 genes associated with human gastric and colorectal cancers. Cancer Res 61:3541-3543
31. Zhang Y, Hiraishi Y, Wang H et al (2005) Constitutive activating mutation of the FGFR3b in oral squamous cell carcinomas. Int J Cancer 117:166-168
32. Aubertin J, Tourpin S, Janot F, Ahomadegbe JC, Radvanyi F (2007) Analysis of fibroblast growth factor receptor 3 G697C mutation in oral squamous cell carcinomas. Int J Cancer 120:2058-2059; author reply 60
33. Hafner C, van Oers JM, Hartmann A et al (2006) High frequency of FGFR3 mutations in adenoid seborrheic keratoses. J Invest Dermatol 126:2404-2407
34. Logie A, Dunois-Larde C, Rosty C et al (2005) Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans. Hum Mol Genet 14:1153
35. Hafner C, van Oers JM, Vogt T et al (2006) Mosaicism of activating FGFR3 mutations in human skin causes epidermal nevi. J Clin Invest 116:2201-2207
36. van Oers JM, Lurkin I, van Exsel AJ et al (2005) A simple and fast method for the simultaneous detection of nine fibroblast growth factor receptor 3 mutations in bladder cancer and voided urine. Clin Cancer Res 11:7743-7748
37. Bakkar AA, Quach V, Le Borgne A et al (2005) Sensitive allele-specific PCR assay able to detect FGFR3 mutations in tumors and urine from patients with urothelial cell carcinoma of the bladder. Clin Chem 51:1555
38. Hartmann A, Moser K, Kriegmair M, Hofstetter A, Hofstaedter F, Knuechel R (1999) Frequent genetic alterations in simple urothelial hyperplasias of the bladder in patients with papillary urothelial carcinoma (In Process Citation). Am J Pathol 154:721-727
39. Obermann EC, Junker K, Stoehr R et al (2003) Frequent genetic alterations in flat urothelial hyperplasias and concomitant papillary bladder cancer as detected by CGH, LOH, and FISH analyses. J Pathol 199:50-57
40. Cairns P, Shaw ME, Knowles MA (1993) Initiation of bladder cancer may involve deletion of a tumour-suppressor gene on chromosome 9. Oncogene 8:1083-1085
41. Chow NH, Cairns P, Eisenberger CF et al (2000) Papillary urothelial hyperplasia is a clonal precursor to papillary transitional cell bladder cancer. Int J Cancer 89:514-518
42. van Oers JM, Adam C, Denzinger S et al (2006) Chromosome 9 deletions are more frequent than FGFR3 mutations in flat urothelial hyperplasias of the bladder. Int J Cancer 119:1212-1215
43. Tomlinson D, Baldo O, Knowles MA (2007) FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer. J Pathol 213:91-98
44. van Rhijn BW, van der Kwast TH, Vis AN et al (2004) FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma. Cancer Res 64:1911-1914
45. Lamy A, Gobet F, Laurent M et al (2006) Molecular profiling of bladder tumors based on the detection of FGFR3 and TP53 mutations. J Urol 176:2686-2689
46. Knowles MA (2006) Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese? Carcinogenesis 27:361-373
47. Esrig D, Spruck CHd, Nichols PW et al (1993) p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am J Pathol 143:1389-1397
48. Mhawech-Fauceglia P, Cheney RT, Fischer G, Beck A, Herrmann FR (2006) FGFR3 and p53 protein expressions in patients with pTa and pT1 urothelial bladder cancer. Eur J Surg Oncol 32:231-237
49. Richter J, Jiang F, Gorog JP et al (1997) Marked genetic differences between stage pTa and stage pT1 papillary bladder cancer detected by comparative genomic hybridization. Cancer Res 57:2860-2864
50. Dalbagni G (2007) The management of superficial bladder cancer. Nat Clin Pract Urol 4:254-60
51. Hart KC, Robertson SC, Kanemitsu MY, Meyer AN, Tynan JA, Donoghue DJ (2000) Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4. Oncogene 19:3309-3320
52. Jebar AH, Hurst CD, Tomlinson DC, Johnston C, Taylor CF, Knowles MA (2005) FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma. Oncogene 24:5218-5225
53. Lopez-Knowles E, Hernandez S, Malats N et al (2006) PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors. Cancer Res 66:7401-7404
54. Cairns P, Evron E, Okami K et al (1998) Point mutation and homozygous deletion of PTEN/MMAC1 in primary bladder cancers. Oncogene 16:3215-3218
55. Aveyard JS, Skilleter A, Habuchi T, Knowles MA (1999) Somatic mutation of PTEN in bladder carcinoma. Br J Cancer 80:904-908
56. Saal LH, Holm K, Maurer M et al (2005) PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 65:2554-2559
57. Byun DS, Cho K, Ryu BK et al (2003) Frequent monoallelic deletion of PTEN and its reciprocal associatioin with PIK3CA amplification in gastric carcinoma. Int J Cancer 104:318-327
58. Oda K, Stokoe D, Taketani Y, McCormick F (2005) High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res 65:10669-10673
59. Zieger K, Dyrskjot L, Wiuf C et al (2005) Role of activating fibroblast growth factor receptor 3 mutations in the development of bladder tumors. Clin Cancer Res 11:7709-7719
60. Dyrskjot L, Kruhoffer M, Thykjaer T et al (2004) Gene expression in the urinary bladder: A common carcinoma in situ gene expression signature exists disregarding histopathological classification. Cancer Res 64:4040-4048
61. Lindgren D, Liedberg F, Andersson A et al (2006) Molecular characterization of early-stage bladder carcinomas by expression profiles, FGFR3 mutation status, and loss of 9q. Oncogene 25:2685-2696
62. Tomlinson DC, L'Hote CG, Kennedy W, Pitt E, Knowles MA (2005) Alternative splicing of fibroblast growth factor receptor 3 produces a secreted isoform that inhibits fibroblast growth factor-induced proliferation and is repressed in urothelial carcinoma cell lines. Cancer Res 65:10441-10449
63. Murgue B, Tsunekawa S, Rosenberg I, deBeaumont M, Podolsky DK (1994) Identification of a novel variant form of fibroblast growth factor receptor 3 (FGFR3 IIIb) in human colonic epithelium. Cancer Res 54:5206-5211
64. Zhang X, Ibrahimi OA, Olsen SK, Umemori H, Mohammadi M, Ornitz DM (2006) Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family. J Biol Chem 281:15694-15700
65. Jang JH (2002) Identification and characterization of soluble isoform of fibroblast growth factor receptor 3 in human SaOS-2 osteosarcoma cells. Biochem Biophys Res Commun 292:378-382
66. Johnston CL, Cox HC, Gomm JJ, Coombes RC (1995) Fibroblast growth factor receptors (FGFRs) localize in different cellular compartments. A splice variant of FGFR-3 localizes to the nucleus. J Biol Chem 270:30643-30650
67. Sturla LM, Merrick AE, Burchill SA (2003) FGFR3IIIS: A novel soluble FGFR3 spliced variant that modulates growth is frequently expressed in tumour cells. Br J Cancer 89:1276-1284
68. Terada M, Shimizu A, Sato N, Miyakaze SI, Katayama H, Kurokawa-Seo M (2001) Fibroblast growth factor receptor 3 lacking the Ig IIIb and transmembrane domains secreted from human squamous cell carcinoma DJM-1 binds to FGFs. Mol Cell Biol Res Commun 4:365-373
69. Chodak GW, Hospelhorn V, Judge SM, Mayforth R, Koeppen H, Sasse J (1988) Increased levels of fibroblast growth factor-like activity in urine from patients with bladder or kidney cancer. Cancer Res 48:2083-2088
70. Chopin DK, Caruelle JP, Colombel M et al (1993) Increased immunodetection of acidic fibroblast growth factor in bladder cancer, detectable in urine. J Urol 150:1126-1130
71. Gravas S, Bosinakou I, Kehayas P, Giannopoulos A (2004) Urinary basic fibroblast growth factor in bladder cancer patients. Histopathological correlation and clinical potential. Urol Int 73:173-177
72. O'Brien T, Cranston D, Fuggle S, Bicknell R, Harris AL (1997) Two mechanisms of basic fibroblast growth factor-induced angiogenesis in bladder cancer. Cancer Res 57:136-140
73. Matsumoto M, Ohtsuki Y, Ochii K et al (2004) Fibroblast growth factor receptor 3 protein expression in urothelial carcinoma of the urinary bladder, exhibiting no association with low-grade and/or non-invasive lesions. Oncol Rep 12:967
74. Gomez-Roman JJ, Saenz P, Molina M et al (2005) Fibroblast growth factor receptor 3 is overexpressed in urinary tract carcinomas and modulates the neoplastic cell growth. Clin Cancer Res 11:459
75. Bernard-Pierrot I, Brams A, Dunois-Larde C et al (2006) Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b. Carcinogenesis 27:740-747
76. Malats N, Bustos A, Nascimento CM et al (2005) P53 as a prognostic marker for bladder cancer: A meta-analysis and review. Lancet Oncol 6:678-686
77. Buscarini M, Quek ML, Gill P, Xia G, Quinn DI, Stein JP (2005) Molecular prognostic factors in bladder cancer. BJU Int 95:739-742
78. Ooms EC, Anderson WA, Alons CL, Boon ME, Veldhuizen RW (1983) Analysis of the performance of pathologists in the grading of bladder tumors. Hum Pathol 14:140-143
79. Tosoni I, Wagner U, Sauter G et al (2000) Clinical significance of interobserver differences in the staging and grading of superficial bladder cancer. BJU Int 85:48-53
80. Harnden P, Mahmood N, Southgate J (1999) Expression of cytokeratin 20 redefines urothelial papillomas of the bladder. Lancet 353:974-977
81. van Oers JM, Wild PJ, Burger M et al (2007) FGFR3 Mutations and a Normal CK20 Staining Pattern Define Low-Grade Noninvasive Urothelial Bladder Tumours. Eur Urol 52(3):760-768
82. Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R (2003) The health economics of bladder cancer: A comprehensive review of the published literature. Pharmacoeconomics 21:1315-1330
83. Sangar VK, Ragavan N, Matanhelia SS, Watson MW, Blades RA (2005) The economic consequences of prostate and bladder cancer in the UK. BJU Int 95:59-63
84. Bastacky S, Ibrahim S, Wilczynski SP, Murphy WM (1999) The accuracy of urinary cytology in daily practice. Cancer 87:118-128
85. van Rhijn BW, van der Poel HG, van der Kwast TH (2005) Urine markers for bladder cancer surveillance: A systematic review. Eur Urol 47:736-748
86. Lokeshwar VB, Soloway MS (2001) Current bladder tumor tests: Does their projected utility fulfill clinical necessity? J Urol 165:1067-1077
87. Steiner G, Schoenberg MP, Linn JF, Mao L, Sidransky D (1997) Detection of bladder cancer recurrence by microsatellite analysis of urine. Nat Med 3:621-624
88. Hoque MO, Lee J, Begum S et al (2003) High-throughput molecular analysis of urine sediment for the detection of bladder cancer by high-density single-nucleotide polymorphism array. Cancer Res 63:5723-5726
89. Schneider A, Borgnat S, Lang H et al (2000) Evaluation of microsatellite analysis in urine sediment for diagnosis of bladder cancer. Cancer Res 60:4617-4622
90. Chen J, Williams IR, Lee BH et al (2005) Constitutively activated FGFR3 mutants signal through PLC{gamma}-dependent and -independent pathways for hematopoietic transformation. Blood 106:328-337
91. Grand EK, Chase AJ, Heath C, Rahemtulla A, Cross NC (2004) Targeting FGFR3 in multiple myeloma: Inhibition of t(4;14)-positive cells by SU5402 and PD173074. Leukemia 18:962-966
92. Trudel S, Ely S, Farooqi Y et al (2004) Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma. Blood 103:3521-3528
93. Trudel S, Li ZH, Wei E et al (2005) CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. Blood 105:2941
94. Trudel S, Stewart AK, Rom E et al (2006) The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells. Blood 107:4039-4046
95. Tomlinson DC, Hurst CD, Knowles MA (2007) Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer. Oncogene 26:5889-5899
96. Weinstein IB (2002) Cancer. Addiction to oncogenes - the Achilles heal of cancer. Science 297:63-64
97. Mohammadi M, McMahon G, Sun L et al (1997) Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. Science 276:955-960
98. Martinez-Torrecuadrada J, Cifuentes G, Lopez-Serra P, Saenz P, Martinez A, Casal JI (2005) Targeting the extracellular domain of fibroblast growth factor receptor 3 with human single-chain Fv antibodies inhibits bladder carcinoma cell line proliferation. Clin Cancer Res 11:6280-6290